Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 2 selected

Guidance programme

Showing 771 to 780 of 911

TitleReference numberPublishedLast updated
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancerTA1042
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancerTA911
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and overHST20
Semaglutide for managing overweight and obesityTA875
Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal)TA910
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndromeHST31
Setmelanotide for treating obesity caused by LEPR or POMC deficiencyHST21
Siponimod for treating secondary progressive multiple sclerosisTA656
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)TA972
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal)TA838

Results per page

  1. 10
  2. 25
  3. 50
  4. All